Page 8 of 10 – SEC Filing
| CUSIP No. 29604W108 | Page 8 of 10 Pages |
| Holder | Number of Ordinary Shares we own or have the right to acquire within 60 days | Percent of Class Outstanding | ||||||
| 667, L.P. | 487,031 | 2.7 | % | |||||
| Baker Brothers Life Sciences, L.P. | 4,411,306 | 24.6 | % | |||||
| Total | 4,898,337 | 27.3 | % | |||||
Pursuant to the management agreements, as amended, among the
Adviser, the Funds and their respective general partners, the Funds’ respective general partners relinquished to the Adviser
all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the
Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over
investments.
The Adviser GP, Felix J. Baker and Julian C. Baker as principals
of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds,
and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.
The Reporting Persons disclaim beneficial ownership of the securities
of the Issuer held by each of the Funds, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are
the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any
such Reporting Person actually exercises voting or dispositive power with respect to such securities.
(c) The disclosure regarding the purchase of ADS of the Issuer
in the Offering described in Item 4 are incorporated by reference herein. Except as described in this Schedule 13D, none of the
Reporting Persons has effected any transaction in the securities of the Issuer during the past 60 days.
(d) Certain securities of the Issuer are held directly by 667,
a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general
partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech
Capital (GP), LLC.
Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.
(e) Not applicable.
Follow Erytech Pharma S.a. (NASDAQ:ERYP)
Follow Erytech Pharma S.a. (NASDAQ:ERYP)
Receive real-time insider trading and news alerts
